-
02.26.2025 | CARB-X announces new round of funding for antibiotics, diagnostics
CIDRAP | CARB-X today announced a new round of funding targeting therapeutics for gram-negative bacterial infections and rapid diagnostics for typhoid fever.
-
02.07.2025 | BioInfect 2025 sees a great turnout for a day of AMR discussion
BIOINFECT | BioInfect returned to The Spine in Liverpool for the second year in a row on 5th February, with over 175 delegates, 14 exhibitors and 15 poster abstracts focusing on the issues surrounding the increasing threat of AMR and how it can be addressed.
-
01.30.2025 | Novo Nordisk Foundation granted DKK 10 billion (€1.35 billion) to benefit people and the planet in milestone year
NOVO NORDISK FOUNDATION | In 2024, on its 100th anniversary, the Novo Nordisk Foundation reached a new milestone, awarding close to DKK 10.1 billion (€1.35 billion) to support nearly 1,800 new projects aimed at improving people’s health and the sustainability of society and the planet.
-
01.27.2025 | Health experts, academics, business leaders and local students will take centre stage at antimicrobial resistance conference as BioInfect returns to Liverpool
BIONOW | Health experts, academics, business leaders and local students will take centre stage at antimicrobial resistance conference as BioInfect returns to Liverpool.
-
01.24.2025 | Muschel (Hera): “In Ue 35mila morti all’anno dovuti all’Amr, la ricerca priorità assoluta”
RIF DAY | Sono cifre da bollettino di guerra: la resistenza agli antibiotici in Europa provoca 35mila decessi all’anno.
-
01.24.2025 | Ministro Schillaci a Davos: ribadito l’impegno a contrastare la piaga della resistenza agli antibiotici
MONDOSANITA | La nostra salute sotto i riflettori in occasione del World Economic Forum di Davos, un evento annuale che riunisce statisti, leader politici, rappresentanti del mondo economico e della società civile.
-
01.22.2025 | Four opportunities to revitalize the US biomedical research enterprise
HEALTH AFFAIRS | The US biomedical research enterprise is renowned for its historical and ongoing scientific breakthroughs and advancements.
-
01.21.2025 | CARB-X funds $3.5M to Melio for rapid neonatal sepsis diagnostic
CONTAGION LIVE | CARB-X has awarded a $3.5 million grant to Melio, a biotechnology company, to develop a rapid diagnostic tool to detect neonatal sepsis.
-
01.13.2025 | How the Global AMR Innovation Fund is leading the fight against antimicrobial resistance
INNOVATION NEWS NETWORK | In a world increasingly shaped by scientific advancements, one of the most pressing challenges is antimicrobial resistance (AMR)—a growing threat to global health, economies, and future generations.
-
01.13.2025 | Collaborative innovation: Reimagining R&D partnerships to create a healthier future for everyone
WORLD ECONOMIC FORUM | Reinventing private, public and philanthropic collaboration could help develop multi-faceted solutions targeting infectious disease, mental health and the health impacts of climate change.
-
01.07.2025 | $2.6 million accelerates anti-biofilm vaccine to prevent bacterial infections
VAX BEFORE TRAVEL | CARB-X today announced it awarded Clarametyx Biosciences $2.6 million to develop an anti-biofilm vaccine.
-
01.07.2025 | CARB-X funds development of anti-biofilm vaccine
CIDRAP | CARB-X today announced an award of $2.6 million to Clarametyx Biosciences to develop an anti-biofilm vaccine.
-
01.03.2025 | Mit „sportlichem Ehrgeiz“: Gießener Forscher tüfteln an neuem Antibiotika-Wirkstoff
Gießener Allgemeine | Forscher aus Gießen arbeiten seit geraumer Zeit an einem neuen Antibiotika-Wirkstoff. Ein Blick hinter die Kulissen einer spannenden Entwicklung, die weit über die Naturwissenschaft hinausgeht.
Toggle navigation